Skip to main content
. 2015 Mar 25;6(11):9502–9516. doi: 10.18632/oncotarget.3321

Figure 1. Bone metastatic phenotype of MDA-MB-231 cells is associated with higher expression of TRAIL-R2 and enhanced proliferation.

Figure 1

Whole cell lysates of MDA-MB-231 and their bone-seeking variant MDA-MB-231-BO were analyzed by Western blot for the expression of depicted proteins (A). As a control for equal gel loading, ß-actin levels were analyzed. (B) Proliferation of parental MDA-MB-231 and bone seeking variant were determined 72 h post seeding. Cell surface (non-permeabilized) and total (permeabilized) levels of TRAIL-R1 and R2 were analyzed by FACS and quantified for the percent of cells (C) and the staining intensity per cell (D) for each death receptor. Graphs represent average values ± SD (n = 5) (*p < 0.05, **p < 0.01, ***p < 0.001).